The license agreement was executed under the direction of UCL Business Ltd (UCLB), part of UCL Innovation & Enterprise. Based on the research of Professor Thomas Voit at the UCL GOSH Institute of Child Health, the agreement covers UCL’s leading expertise in gene therapy.“Early stage partnerships are critical to expedite innovation in gene therapy research and development. UCL is one of the world’s leading research centers and is ideally suited to help us expand our pipeline of gene therapies for cardiomyopathies,” said Dr. Valeria Ricotti, chief medical officer at DiNAQOR.
Where others have failed will Atl1102 succeed ?, page-904
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.6¢ | 7.5¢ | $13.48K | 179.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 254315 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.8¢ | 97444 | 1 |
View Market Depth
| Last trade - 12.35pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.5¢ |
Change
0.000 ( 3.60 %) |
||||
| Open | High | Low | Volume | ||
| 7.5¢ | 7.5¢ | 7.5¢ | 50815 | ||
| Last updated 12.35pm 22/05/2024 ? | |||||
| PER (ASX) Chart |